Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q86Y91
UPID:
KI18B_HUMAN
Alternative names:
-
Alternative UPACC:
Q86Y91; A0A0C4DGP2; A0A0C4DGP5; A6NJI2; B7ZM49; B9EGM8; D5L6I1
Background:
Kinesin-like protein KIF18B, in complex with KIF2C, plays a pivotal role in mitotic cell division by depolymerizing microtubules at their plus ends. This action is crucial for the proper segregation of chromosomes. KIF18B's interaction with MAPRE1 and its transportation along microtubules underscore its significance in cellular dynamics and division.
Therapeutic significance:
Understanding the role of Kinesin-like protein KIF18B could open doors to potential therapeutic strategies. Its critical function in cell division highlights its potential as a target in cancer therapy, where uncontrolled cell division is a hallmark.